(Q38875984)

7 September 2017

title

Induction of opsonophagocytic killing activity with pneumococcal conjugate vaccine in human immunodeficiency virus-infected Ugandan adults (English)

1 reference

pneumococcal conjugate vaccine

7 September 2017

0 references

1 reference

9

Cissy Kityo

1 reference

7 September 2017

11

Peter Mugyenyi

1 reference

7 September 2017

2

Francis Ssali

1 reference

7 September 2017

Meng Chen

1

1 reference

7 September 2017

Maureen Mulungi

3

1 reference

7 September 2017

Peter Awio

4

1 reference

7 September 2017

Hiroyuki Yoshimine

5

1 reference

7 September 2017

Reiki Kuroki

6

1 reference

7 September 2017

Akitsugu Furumoto

7

1 reference

7 September 2017

Susumu Tanimura

8

1 reference

7 September 2017

Tsuyoshi Nagatake

10

1 reference

7 September 2017

Kazunori Oishi

12

1 reference

7 September 2017

language of work or name

English

0 references

publication date

17 July 2008

1 reference

7 September 2017

1 reference

7 September 2017

volume

26

1 reference

7 September 2017

issue

38

1 reference

7 September 2017

page(s)

4962-4968

1 reference

Natural and vaccine-related immunity to Streptococcus pneumoniae

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.093

Opsonization and antibodies to capsular and cell wall polysaccharides of Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.093

CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.093

Antibody-independent, CD4+ T-cell-dependent protection against pneumococcal colonization elicited by intranasal immunization with purified pneumococcal proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.093

HIV and pneumococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.093

Decreased Serum Opsonic Activity against Streptococcus pneumoniae in Human Immunodeficiency Virus--Infected Ugandan Adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.093

Lung Fluid Immunoglobulin from HIV-Infected Subjects Has Impaired Opsonic Function against Pneumococci

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.093

Global strategies to prevent bacterial pneumonia in adults with HIV disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.093

Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.093

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.093

Responsiveness of human immunodeficiency virus type 1-infected Kenyan women with or without prior pneumococcal disease to pneumococcal vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.093

Pneumococcal vaccination in HIV-1-infected adults in Uganda: humoral response and two vaccine failures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.093

23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.093

23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.093

Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.093

Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.093

Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.093

Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.093

Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.093

Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.093

Expression of chemokine receptors on CD4+ T cells in peripheral blood from HIV-infected individuals in Uganda

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.093

Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.093

Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.093

Specificity of the antibody response to the pneumococcal polysaccharide and conjugate vaccines in human immunodeficiency virus-infected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.093

Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.093

Optimization of nb-4 and hl-60 differentiation for use in opsonophagocytosis assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.093

Emergence of antibody to capsular polysaccharides of Streptococcus pneumoniae during outbreaks of pneumonia: association with nasopharyngeal colonization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.093

Persistence of antibody response to pneumococcal capsular polysaccharides in vaccinated long term-care residents in Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.093

Antibody Responses to Nasopharyngeal Carriage ofStreptococcus pneumoniaein Adults: A Longitudinal Household Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.093

Use of HL-60 cell line to measure opsonic capacity of pneumococcal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.093

Relationship of in vitro phagocytosis of serotype 14 Streptococcus pneumoniae to specific class and IgG subclass antibody levels in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.093

Functional antibodies elicited by an 11-valent diphtheria-tetanus toxoid-conjugated pneumococcal vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.093

Functional activity of antibodies after immunization of Finnish and Israeli infants with an 11-valent pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.093

Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.093

10.1016/J.VACCINE.2008.06.093

7 January 2021

Identifiers

DOI

1 reference

7 September 2017

1 reference